Talapatra Quoted on Caraco Pharmaceutical v. Novo Nordisk

20 April 2012 FDA Week News

FDA Week

Associate Sunit Talapatra said the Supreme Court’s ruling in Caraco Pharmaceutical v. Novo Nordisk could influence other legal interpretations of the generic drug framework due to the decision’s broad statutory context. However, Talapatra noted that the facts of Caraco are unique to the case and not likely to result in a stratified field of litigation based on use codes.

Related Services